SPREAD-DIMCAD\(^1\) – Cardiovascular (CV) Outcomes Trial Summary
Effect of Metformin Versus Glipizide \textsubscript{Glucom}\(^1\) on Cardiovascular Outcomes in Patients with Type 2 Diabetes (T2DM) & Coronary Artery Disease (CAD)

**Trial Background:** n=304 patients with T2DM with hx of CAD

- Metformin 500mg TID vs glipizide 10mg TID (after titration from half target dose). Higher doses could be tried as necessary & insulin could be added after 3 months if glucose control not achieved 4.1% <7%, FPG <7mmol/L, PPBG <10mmol/L.
- Randomized, concealed allocation probable, double-blind, multicenter, 15 centres in China
- Primary outcome: composite of recurrent CV events: non-fatal MI, nonfatal stroke, arterial revascularization by percutaneous transluminal coronary angioplasty or coronary artery bypass graft, CV death, or all-cause death
- **INCLUSION:** T2DM (WHO 1999 criteria) CAD (hx of actue MI or stenosis >50% of lumen diameter in at least 1 major epicardial coronary artery), \(\Delta & \Omega < 80\) yrs
- **EXCLUSION:** severe liver dx, NYHA class III, psychiatric disease, severe infection, severe anemia, or neutropenia, other severe organ heart diseases, insulin-dependent T2DM, pregnant or lactating, recent drug or alcohol abuse

**Baseline Characteristics:** \(\delta\alpha\), ethnicity: Chinese; age: 63 mean\(^1\); weight: 69 kg mean, duration of diabetes 5.6 yrs; duration of CAD 3 years mean\(^2\); A1C 7.6% mean; SCR 98.8-18.9 umol/L; hypertension 67.71%, prior MI 53.63%, prior stroke 13.18%, prior arterial revascularization 62.64%, 80% significant baseline differences between CV & T2DM medications.

**Table 1: Results: 1\(^{st}\) & 2\(^{nd}\) Endpoints - study period for 3 years; median follow-up of 1\(^{st}\) endpoint was 5 years** (ITT analysis)

<table>
<thead>
<tr>
<th>Clinical Endpoints</th>
<th>Glipizide n=148</th>
<th>Metformin n=156</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1(^{st}) Composite CV events (5 \times 6), non-fatal stroke (10 \times 15), arterial revascularization (21 \times 25), all-cause death (7 \times 14)</td>
<td>at 5 yrs</td>
<td>at 5 yrs</td>
<td>Primary (1^{st}) composite endpoint @5yr: Metformin ↓ risk HR=0.45, 95%CI 0.30-0.79; RRR 31.0/35.7% vs 29%; NNT: 10 / over 5 years</td>
</tr>
<tr>
<td>2(^{nd}) Cardiovascular endpoints glipizide vs metformin:</td>
<td></td>
<td></td>
<td>At end of follow up: Glipizide n=97; Metformin n=111</td>
</tr>
<tr>
<td>• No significant differences in individual endpoints (at 3 yrs) {New or worsening angina 48.4% vs 49.9% new or worsening heart failure 6.8% vs 5.8%, new critical cardiac arrhythmia (18.2% \times 19.2%), &amp; new peripheral vascular events 0.6% vs 4.1% (p=0.005)}</td>
<td>35% (\text{mean} \pm \text{SD} = 0.52)</td>
<td>25% (\text{mean} \pm \text{SD} = 0.39)</td>
<td></td>
</tr>
</tbody>
</table>

**Strengths, Limitations & Uncertainties**

**Strengths**
- first double-blind randomized, RCT to compare different effects of glipizide and metformin in major CV events among pts with CAD and T2DM; use of CV meds were well controlled for in this study
- extends the generalizability of UKPDS-34 to high-risk patients with existing diabetes\(^{3}\)

**Limitations**
- trial used glipizide to represent SU but various SUs may differ in their effects on glucose control & CV risk in T2DM patients
- the trial did not have a wash-out period • relatively small trial some variation in baseline characteristics

**Comments:**
- The authors postulate that metformin’s benefits may be due antiatherogenic effects beyond its antihyperglycemic action. Research has postulated that metformin may work by altering hepatic lipogenesis, increasing the sensitivity of insulin.\(^2\)
- Uncertainties: Are outcomes similar with all sulfonylureas? What is the association between A1C & macrovascular events?

**The Bottom Line**
- When considering the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction/stroke, arterial revascularization and all-cause death, metformin was associated with a greater reduction in cardiovascular events compared to glipizide in patients with T2DM and CAD despite achieving similar A1C levels.
- This is the first RCT to directly compare the effect of a sulfonylurea (glipizide not available in Canada\(^1\)) and metformin on the recurrence of major cardiovascular events in high risk “CAD” patients with existing diabetes. It is consistent with the findings of the UKPDS-34 where a reduction in macrovascular events, all-cause death \(\text{NNT}=14/10y\) was also seen with metformin in obese T2DM patients despite less A1C lowering than that of the sulfonylurea & insulin group \(\text{UKPDS-33}\).

See also: Diabetes Agents - Outcomes Summary Table: [http://www.rxfiles.ca/rxfiles/uploads/documents/Diabetes_Agents_Outcomes_Comparison_Summary_Table.pdf](http://www.rxfiles.ca/rxfiles/uploads/documents/Diabetes_Agents_Outcomes_Comparison_Summary_Table.pdf)

**References:**

**DISCLAIMER:** The content of this newsletter represents the views, opinions and position of the author and not those of the Board or Management of Saskatoon Health Region (SHR). Neither the author nor Saskatoon Health Region nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions for the result obtained from the use of such information. Any use of the newsletter will signify acknowledgment of this disclaimer and release any responsibility of SHR, its employees, agents or contractors. RxFiles Trial Summary – Nov 2013 J Lui, L Regier - [www.RxFiles.ca](http://www.RxFiles.ca) – Nov 2013 Copyright 2013 – RxFiles, Saskatoon Health Region (SHR) - [www.RxFiles.ca](http://www.RxFiles.ca)